Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Dose Escalation Single-dose Study of RV-001 in Retinitis Pigmentosa
jRCT2033240611Phase 2Recruiting
- Sponsor
- Restore Vision Inc.
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of teprotumumab in retinitis pigmentosa (RP), sponsored by Restore Vision Inc. Primary endpoint: Dose-Limiting Toxicity. Started Feb 2025; status: recruiting.
02
Drugs
teprotumumab
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on jRCT2033240611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033240611.